$Cerus (CERS.US)$
Cerus Corporation Announces Receipt of CE Mark for Next-Generation INTERCEPT Illumination Device (INT200)
Wednesday, 5th March at 1:00 pm
Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union
Cerus Corporation (NASDAQ: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union...

$Cerus (CERS.US)$ Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
 Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively from Prior Year Periods
 Fourth straight quarter of positive operating cash flows
 Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million

$Cerus (CERS.US)$  up up up

$Cerus (CERS.US)$ Reuters· 4 mins ago
Cerus Corp - Extends Supply and Manufacturing Agreement With Porex Until Dec 31, 2027

$Cerus (CERS.US)$ Financial Performance:
Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
Operating expenses in Q3 amounted to $31.8...

$Cerus (CERS.US)$
Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million

$Cerus (CERS.US)$$Cerus (CERS.US)$ is scheduled to release its financial results post-market on October 30 ET.
Earnings Preview
Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
The accounting standard used for the above data is US-GAAP.

$Cerus (CERS.US)$ TD Cowen analyst Josh Jennings maintains $Cerus (CERS.US)$ with a buy rating, and maintains the target price at $5.

$Cerus (CERS.US)$
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
In Europe, the CE ...